Collegium Pharmaceutical, Inc. (COLL) Operating income 2016–2025
Collegium Pharmaceutical, Inc. (COLL) annual operating income history from SEC filings — each fiscal year as reported.
$179.6MFY2025 · since FY2016: -$94.1M → $179.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $179.6M | +5.7% |
| FY2024 | $169.9M | +1.8% |
| FY2023 | $167.0M | +401.1% |
| FY2022 | $33.3M | +89.0% |
| FY2021 | $17.6M | -68.7% |
| FY2020 | $56.2M | +336.8% |
| FY2019 | -$23.7M | -14.8% |
| FY2018 | -$20.7M | +72.6% |
| FY2017 | -$75.4M | +19.8% |
| FY2016 | -$94.1M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More COLL financial trends
COLL RevenueCOLL Net incomeCOLL Net marginCOLL Gross profitCOLL Gross marginCOLL Operating marginCOLL Operating cash flowCOLL Free cash flowCOLL Capital expendituresCOLL Return on equityCOLL Stock buybacksCOLL Dividends paidCOLL Total assetsCOLL Total liabilitiesCOLL Shareholders’ equityCOLL overview →